Repligen Corporation ($RGEN) Stock Forecast: Down 6.1% Today

What is Repligen Corporation?

Repligen Corporation (NASDAQ: RGEN) is a biotechnology company specializing in bioprocessing products. Today, RGEN experienced a strong bearish movement in the market.

Why is Repligen Corporation going down?

RGEN stock is down 6.1% on Feb 5, 2026 15:53

• The bearish movement in RGEN's stock price could be attributed to significant insider selling activity by company executives and institutional investors reducing their holdings.
• Despite the positive long-term outlook, the near and mid-term sentiment appears weak, leading to a downside target of 13.3%.
• The mixed institutional investor activity, with some increasing and others decreasing their positions, might have added to the selling pressure on RGEN's stock.
• The overall market sentiment towards RGEN remains cautiously optimistic, as indicated by the "Moderate Buy" consensus rating from Wall Street analysts with an average price target of $179.62.

RGEN Price Chart

RGEN Technical Analysis

RGEN News

Why (RGEN) Price Action Is Critical for Tactical Trading

This article analyzes Repligen Corporation (NASDAQ: RGEN) stock, highlighting a weak near and mid-term sentiment despite a long-term positive outlook. It identifies a mid-channel oscillation pattern and an exceptional short setup with a 46.4:1 risk-reward ratio, targeting a 13.3% downside. Three distinct AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) are provided, along with multi-timeframe signal analysis.

https://news.stocktradersdaily.com/news_release/52/Why_RGEN_Price_Action_Is_Critical_for_Tactical_Trading_020426105601_1770263761.html

WCM Investment Management LLC Trims Holdings in Repligen Corporation $RGEN

WCM Investment Management LLC significantly reduced its stake in Repligen Corporation (NASDAQ:RGEN) by 38.1% in the third quarter, now holding 67,999 shares valued at $8.44 million. Despite this, other institutional investors either increased their holdings or initiated new positions, and Wall Street analysts maintain a "Moderate Buy" consensus with an average price target of $179.62. Company insiders have been net sellers, disposing of shares worth approximately $7.72 million over the past 90 days.

https://www.marketbeat.com/instant-alerts/filing-wcm-investment-management-llc-trims-holdings-in-repligen-corporation-rgen-2026-02-04/

Mirae Asset Global Investments Co. Ltd. Sells 10,260 Shares of Repligen Corporation $RGEN

Mirae Asset Global Investments Co. Ltd. reduced its stake in Repligen Corporation by 34.8%, selling 10,260 shares and holding 19,262 shares valued at $2.575 million. Company insiders have also been net sellers, with 49,657 shares sold over the last three months. Despite insider selling, analyst sentiment remains broadly positive, with a "Moderate Buy" consensus and an average price target of $179.62.

https://www.marketbeat.com/instant-alerts/filing-mirae-asset-global-investments-co-ltd-sells-10260-shares-of-repligen-corporation-rgen-2026-02-03/

Brown Capital Management LLC Reduces Stock Holdings in Repligen Corporation $RGEN

Brown Capital Management LLC has reduced its stake in Repligen Corporation by 33.5% in the third quarter, now owning 668,858 shares valued at $89.4 million, which constitutes 3.7% of its portfolio. Despite insider selling activity, the consensus analyst rating for Repligen remains "Moderate Buy" with an average price target of $179.62. The biotechnology company, specializing in bioprocessing products, has seen mixed institutional investor activity with some increasing and others decreasing their positions.

https://www.marketbeat.com/instant-alerts/filing-brown-capital-management-llc-reduces-stock-holdings-in-repligen-corporation-rgen-2026-02-03/

Thrivent Financial for Lutherans Increases Stock Holdings in Repligen Corporation $RGEN

Thrivent Financial for Lutherans significantly increased its stake in Repligen Corporation (NASDAQ:RGEN) by 6.7% in the third quarter of 2025, now owning 458,820 shares valued at approximately $61.33 million. This comes despite recent insider selling by the company's director and COO. Analysts currently give Repligen a "Moderate Buy" rating with an average target price of $179.62, while the stock recently opened at $149.37.

https://www.marketbeat.com/instant-alerts/filing-thrivent-financial-for-lutherans-increases-stock-holdings-in-repligen-corporation-rgen-2026-02-02/

Trending Today

Bitcoin ($BTC) Crypto Forecast: Up 9.8% Today

Ethereum ($ETH) Crypto Forecast: Up 13.2% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 11.3% Today

BlackLine, Inc. ($BL) Stock Forecast: Up 5.1% Today

Crowdstrike Holdings Inc. ($CRWD) Stock Forecast: Up 5.0% Today

Chewy Inc ($CHWY) Stock Forecast: Up 5.1% Today

International Paper Company ($IP) Stock Forecast: Up 5.8% Today

Coupang LLC ($CPNG) Stock Forecast: Up 5.1% Today

Oracle Corporation ($ORCL) Stock Forecast: Up 5.1% Today

Aurora Cannabis Inc. ($ACB) Stock Forecast: Up 5.0% Today

Repligen Corporation Price History

14.00.2026 - RGEN Stock was down 5.1%

• AI models analyzing RGEN suggest choppy conditions and conflicting sentiment across various time horizons.
• Institutional trading strategies suggest positions, momentum breakouts, and risk hedging with specified entry, target, and stop-loss levels.
• Multi-timeframe signal strengths, support, and resistance levels paint a challenging outlook for RGEN in the near-term, mid-term, and long-term.
• The bearish movement in RGEN's stock price is possibly due to the choppy market conditions and conflicting sentiment identified in the AI analysis, which have led to heightened selling pressure and a downward trend in the stock.

05.01.2026 - RGEN Stock was down 6.1%

• The bearish movement in RGEN's stock price could be attributed to significant insider selling activity by company executives and institutional investors reducing their holdings.
• Despite the positive long-term outlook, the near and mid-term sentiment appears weak, leading to a downside target of 13.3%.
• The mixed institutional investor activity, with some increasing and others decreasing their positions, might have added to the selling pressure on RGEN's stock.
• The overall market sentiment towards RGEN remains cautiously optimistic, as indicated by the "Moderate Buy" consensus rating from Wall Street analysts with an average price target of $179.62.

21.10.2025 - RGEN Stock was up 5.5%

• The rise in RGEN's stock price is possibly a result of favorable investor sentiment towards the company's P/E ratio.
• Despite a slight decline in the previous month, the substantial increase in the stock price over the last year indicates promising long-term growth prospects, which may have attracted investors.
• The 0.65% increase in the current market session could also be influenced by general market positivity or specific industry trends benefiting biopharmaceutical firms like Repligen Inc.

07.04.2025 - RGEN Stock was down 6.5%

• Repligen Corporation's stock, RGEN, exhibited a decline today, possibly attributed to profit-taking by investors following a period of strong growth.
• A comparative analysis between QGEN and RGEN could have triggered uncertainty among investors, leading to the selling pressure on RGEN shares.
• The anticipation surrounding the upcoming investor conferences might have prompted some investors to reassess their positions in RGEN, contributing to the downward trend.
• In summary, today's bearish movement in RGEN could be linked to profit-taking, comparative analysis with QGEN, and investor sentiment around the forthcoming conferences.

22.07.2025 - RGEN Stock was up 5.4%

• The company revealed its involvement in three forthcoming investor conferences, hinting at possible growth prospects.
• Repligen's participation in these conferences could be perceived as a tactic to appeal to more investors and highlight its advancements in bioprocessing technology.
• Investors might interpret Repligen's proactive engagement with the investment community as a vote of confidence in its future potential, potentially attracting more buyers and boosting the stock price.

06.04.2025 - RGEN Stock was down 6.6%

• Despite reporting strong Q1 earnings and raising revenue guidance for 2025, the market may have had higher expectations, resulting in a sell-off.
• Investors might be favoring QIAGEN (QGEN) over Repligen (RGEN) as a more attractive value stock, impacting RGEN's stock price.
• The bearish movement could be due to profit-taking by traders who had bought the stock in anticipation of positive earnings, causing a temporary decline in the stock price.

01.07.2025 - RGEN Stock was down 5.4%

• The stock's downward trend, which has persisted for over 1400 days, may have contributed to the bearish movement.
• While Repligen announced a strategic partnership with Novasign for bioprocessing digitalization, investors appeared more concerned about the long-term downtrend and associated risks.
• Market sentiment appears to have been influenced by technical analysis and Adhishthana principles, signaling ongoing weakness in the stock and leading to today's bearish movement.

17.06.2025 - RGEN Stock was up 5.0%

• Repligen Corporation announced the upcoming release of its second-quarter 2025 financial results, creating anticipation and positive sentiment among investors.
• The market might be reacting positively to the potential growth and performance indicators that could be revealed during the earnings call.
• Investors seem optimistic about Repligen's future prospects, leading to increased buying activity and driving the stock price higher.
• The strong bullish movement could be a reflection of confidence in Repligen's business strategies and financial health, as hinted by the upcoming financial report.

03.05.2025 - RGEN Stock was up 5.2%

• Upward trends are noticeable among options traders for Repligen (RGEN) stock, reflecting a positive market sentiment.
• The increased engagement in the options market implies expectations of favorable updates or progress related to Repligen's operations.
• This upsurge in positive activity may be linked to possible future collaborations, product introductions, or robust financial results, stimulating investor confidence and elevating the stock value.

23.09.2025 - RGEN Stock was up 5.4%

• Despite initial expectations of a decline in Q3 earnings, Repligen (RGEN) demonstrated a strong bullish performance, potentially signaling investor focus on other positive aspects.
• A comparison of Repligen (RGEN) with Alkermes (ALKS) may have contributed to increased investor interest, supporting the upward momentum in the market.
• Market sentiment towards Repligen (RGEN) potentially improved due to factors beyond earnings, such as anticipated growth opportunities or strategic advancements.

31.09.2025 - RGEN Stock was up 5.0%

• Despite strong Q3 earnings, with revenue growth surpassing expectations, Repligen (RGEN) witnessed a stock dip possibly due to revised EPS guidance.
• The current bullish market trend for RGEN implies a reevaluation of the initial response to the earnings, indicating a perceived undervaluation of the stock.
• Positive surprises in both earnings and revenues for Q3 may have boosted investor confidence, leading to increased buying activity and a rise in stock price.
• The uptrend in RGEN today may stem from investors revisiting the company's performance and recognizing it as a more appealing investment opportunity, despite the initial setback.

28.09.2025 - RGEN Stock was down 6.0%

• Despite exceeding earnings and revenue forecasts in Q3, Repligen (RGEN) faced a bearish trend, potentially triggering investor sell-off.
• Market sentiment towards Repligen may have been impacted by comparisons with Alkermes (ALKS) in terms of value, contributing to the stock's bearish performance.
• Investors seemed to have responded to the positive earnings results by selling shares to secure profits, resulting in a temporary dip in the stock's value.